Loading... Please wait... Loading... Please wait...
ESTIMATED
10/03/2023
10/03/2023
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 0 | -$1.00 | -$1.00 | -$1.00 |
| Q2 2024 | 0 | -$1.00 | -$1.00 | -$1.00 |
| Q3 2024 | 0 | -$0.60 | -$0.60 | -$0.60 |
| Q4 2024 | 0 | -$1.00 | -$1.00 | -$1.00 |
Akari Therapeutics, Plc last posted its earnings results on Tuesday, October 3rd, 2023. The company reported $-0.64958 earnings per share for the quarter, topping analysts' consensus estimates of $-1 by $0.35042. The company had revenue of 0 for the quarter and had revenue of 0 for the year. Akari Therapeutics, Plc has generated $-2 earnings per share over the last year ($-2.04 diluted earnings per share) and currently has a price-to-earnings ratio of -1.17. Akari Therapeutics, Plc has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Friday, September 27th, 2024 based on prior year's report dates.
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue | 03/29/2024 | Q1 2024 | -$0.83 | $0 | $0 | 12/30/2023 | Q4 2023 | -$0.65 | $0 | $0 | 09/28/2023 | Q3 2023 | -$0.65 | $0 | 09/29/2023 | Q2 2023 | -$0.68 | $0 | 03/30/2023 | Q1 2023 | $0.27 | $0 | 12/30/2022 | Q4 2022 | -$1.01 | $0 | 09/29/2022 | Q3 2022 | -$1.01 | $0 | 09/27/2022 | Q2 2022 | -$0.09 | $0 | 05/17/2022 | Q1 2022 | -$0.10 | $0 | 12/03/2021 | Q4 2021 | -$0.12 | $0 | 09/30/2021 | Q3 2021 | -$0.03 | $0 | 06/29/2021 | Q2 2021 | -$0.11 | $0 | 04/20/2021 | Q1 2021 | -$3.04 | $0 | 12/11/2020 | Q4 2020 | -$5.19 | $0 | 09/29/2020 | Q3 2020 | $0.54 | $0 | 09/01/2020 | Q2 2020 | -$5.54 | $0 | 03/31/2020 | Q1 2020 | -$2.69 | $0 | 03/30/2020 | Q4 2019 | -$7.30 | $0 | 11/27/2019 | Q3 2019 | -$2.60 | $0 | 06/06/2019 | Q2 2019 | -$5.12 | $0 |
|---|
A. Akari Therapeutics, Plc has not confirmed its next earnings publication date, but the company's estimated earnings date is Friday, September 27th, 2024 based off last year's report dates.
A. In the previous quarter, Akari Therapeutics, Plc (NASDAQ:AKTX) reported $-0.64958 earnings per share (EPS) to beat the analysts' consensus estimate of $-1 by $0.35042.
A. The conference call for Akari Therapeutics, Plc's latest earnings report can be listened to online.
A. The conference call transcript for Akari Therapeutics, Plc's latest earnings report can be read online.
A. Akari Therapeutics, Plc (NASDAQ:AKTX) has a recorded net income of $0. Akari Therapeutics, Plc has generated $-2.04 earnings per share over the last four quarters.
A. Akari Therapeutics, Plc (NASDAQ:AKTX) has a price-to-earnings ratio of -1.17 and price/earnings-to-growth ratio is -0.14.
